Apolipoprotein A-I inhibits chemotaxis, adhesion, activation of THP-1 cells and improves the plasma HDL inflammatory index

Cytokine

Volumn 49, Issue 2, 2010, Pages 194-200

  Wang, Li ^a   Chen, Wei Zhong ^a   Wu, Man Ping ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Adhesion molecules; Human apolipoprotein A I (ApoA I); MCP 1; Plasma HDL inflammatory index; THP 1 cells

Indexed keywords

APOLIPOPROTEIN A1; CD11B ANTIGEN; CD14 ANTIGEN; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CELL ACTIVATION; CELL ADHESION; CELL MIGRATION; CELLULAR DISTRIBUTION; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INFLAMMATION; MALE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT;

ANIMALS; APOLIPOPROTEIN A-I; CELL ADHESION; CELL LINE, TUMOR; CHEMOTAXIS; HUMANS; LIPOPROTEINS, HDL; MALE; MONOCYTES; NF-KAPPA B; RABBITS; RANDOM ALLOCATION;

ORYCTOLAGUS CUNICULUS;

EID: 73649139907     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2009.08.008     Document Type: Article

References (53)

1. Tardif J.C., Heinonen T., and Noble S. High-density lipoprotein/apolipoprotein A-I infusion therapy. Curr Atheroscler Rep 11 (2009) 58-63
2. Gordon D.J., Probstfield J.L., Garrison J.R., Neaton J.D., Castelli W.P., Knoke J.D., et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79 (1989) 8-15
3. Lewis G.F., and Rader D.J. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96 (2005) 1221-1232
4. Negre-Salvayre A., Dousset N., Ferretti G., Bacchetti T., Curatola G., and Salvayre R. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radical Biol Med 41 (2006) 1031-1040
5. Mineo C., Deguchi H., Griffin J.H., and Shaul P.W. Endothelial and antithrombotic actions of HDL. Circ Res 98 (2006) 1352-1364
6. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., and Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 353 (1991) 265-267
7. Rahaman S.O., Lennon D.J., Febbraio M., Podrez E.A., Hazen S.L., and Silverstein R.L. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab 4 (2006) 211-221
8. Diamond M.S., Staunton D.E., Marlin S.D., and Springer T.A. Binding of the integrin Mac-1(CD11b/CD18) to the third immunoglobulin-like domain of ICAM-1 (CD54) and its regulation by glycosylation. Cell 65 (1991) 961-971
9. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76 (1994) 301-314
10. Cockerill G.W., Rye K.A., Gamble J.R., Vadas M.A., and Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15 (1995) 1987-1994
11. Nicholls S.J., Dusting G.J., Cutri B., Bao S., Drummond G.R., Rye K.A., et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111 (2005) 1543-1550
12. Murphy A.J., Woollard K.J., Hoang A., Mukhamedova N., Stirzaker R.A., McCormick S.P.A., et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 28 (2008) 2071-2077
13. Ma J., Liao X.L., Lou B., and Wu M.P. Role of apolipoprotein A-I in protecting against endotoxin toxicity. Biochim Biophys Acta 36 (2004) 419-424
14. McDonald M.C., Dhadly P., Cockerill G.W., Cuzzocrea S., Mota-Filipe H., Hinds C.J., et al. Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. Shock 20 (2003) 551-557
15. Yan Y.J., Li Y., Lou B., and Wu M.P. Beneficial effects of ApoA-I on LPS-induced acute lung and endotoxemia in mice. Life Sci 79 (2006) 210-215
16. Jiao Y.L., and Wu M.P. Apolipoprotein A-I diminishes acute lung injury and sepsis in mice induced by lipoteichoic acid. Cytokine 43 (2008) 83-87
17. Li Y., Dong J.B., and Wu M.P. Human ApoA-I overexpression diminishes LPS-induced systemic inflammation and multiple organ damage in mice. Eur J Pharmacol 590 (2008) 417-422
18. Liao X.L., Lou B., Ma J., and Wu M.P. Neutrophils activation can be diminished by apolipoprotein A-I. Life Sci 77 (2005) 325-335
19. Gu S.S., Shi N., and Wu M.P. The protective effect of ApolipoproteinA-I on myocardial ischemia-reperfusion injury in rats. Life Sci 81 (2007) 702-709
20. Shi N., and Wu M.P. ApolipoproteinA-I attenuates renal ischemia/reperfusion injury in rats. J Biomed Sci 15 (2008) 577-583
21. Subbanagounder G., Watson A.D., and Berliner J.A. Bioactive products of phospholipid oxidation: isolation, identification, measurement and activities. Free Radical Biol Med 28 (2000) 1751-1761
22. Subbanagounder G., Wong J.W., Lee H., Faull K.F., Miller E., Witztum J.L., et al. Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis: formation of these oxidized phospholipids in response to interleukin-1β. J Biol Chem 277 (2002) 7271-7281
23. Lerch P.G., Förtsch V., Hodler G., and Bolli R. Production and characterization of a reconstituted high density lipoprotein for therapeutic applications. Vox Sang 71 (1996) 155-164
24. Ulrich-Merzenich G., Metzner C., Bhonde R.R., Malsch G., Schiermeyer B., and Vetter H. Simultaneous isolation of endothelial and smooth muscle cells from human umbilical artery or vein and their growth response to low-density lipoproteins. In Vitro Cell Dev Biol Anim 38 (2002) 265-272
25. Kinard F., Jaworski K., Sergent-Engelen T., Goldstein D., van Veldhoven P.P., Holvoet P., et al. Smooth muscle cells influence monocyte response to LDL as well as their adhesion and transmigration in a coculture model of the arterial wall. J Vasc Res 38 (2001) 479-491
26. Keiper T., Al-Fakhri N., Chavakis E., Athanasopoulos A.N., Isermann B., Herzog S., et al. The role of junctional adhesion molecule-C (JAM-C) in oxidized LDL-mediated leukocyte recruitment. FASEB J 19 (2005) 2078-2080
27. Cobb R.R., Felts K.A., McKenzie T.C., Parry G.C.N., and Mackman N. A benzothiophene-carboxamide is a potent inhibitor of IL-1β induced VCAM-1 gene expression in human endothelial cells. FEBS Lett 382 (1996) 323-326
28. Tamai R., Sugawara S., Takeuchi O., Akira S., and Takada H. Synergistic effects of lipopolysaccharide and interferon-γ in inducing interleukin-8 production in human monocytic THP-1 cells is accompanied by up-regulation of CD14, Toll-like receptor 4, MD-2 and MyD88 expression. J Endotoxin Res 9 (2003) 145-153
29. Zhou J.Y., Tang F.D., Mao G.G., and Bian R.L. Effect of α-pinene on nuclear translocation of NFκB in THP-1 cells. Acta Pharmacol Sin 25 (2004) 480-484
30. Navab M., Hama S.Y., Hough G.P., Subbanagounder G., Reddy S.T., and Fogelman A.M. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 42 (2001) 1308-1317
31. Ansell B.J., Navab M., Hama S., Kamranpour N., Fonarow G., Hough G., et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108 (2003) 2751-2756
32. Glass C.K., and Witztum J.L. Atherosclerosis: the road ahead. Cell 104 (2001) 503-516
33. Libby P., Ridker P.M., and Maseri A. Inflammation and atherosclerosis. Circulation 105 (2002) 1135-1143
34. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
35. Lehr H.A., Krombach F., Munzing S., Bodlaj R., Glaubitt S.I., Seiffge D., et al. In vitro effects of oxidized low density lipoprotein on CD11b/CD18 and L-selectin presentation on neutrophils and monocytes with relevance for the in vivo situation. Am J Pathol 146 (1995) 218-227
36. Liao L., Starzyk R.M., and Granger D.N. Molecular determinants of oxidized low-density lipoprotein-induced leukocyte adhesion and microvascular dysfunction. Arterioscler Thromb Vasc Biol 17 (1997) 437-444
37. McGinley M.D., Narhi L.O., Kelley M.J., Davy E., Robinson J., Rohde M.F., et al. CD14: physical properties and identification of an exposed site that is protected by lipopolysaccharide. J Biol Chem 270 (1995) 5213-5218
38. Ulevitch R.J., and Tobias P.S. Recognition of endotoxin by cells leading to transmembrane signaling. Curr Opin Immunol 6 (1994) 125-130
39. Chu A.J., and Prasad J.K. Antagonism by Il-4 and Il-10 of endotoxin-induced tissue factor activation in monocytic THP-1 cells: activating role of CD14 ligation. J Surg Res 80 (1998) 80-87
40. Rosse W.F. Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria. Blood 75 (1990) 1595-1601
41. Ferrero E., Jiao D., Tsuberi B.Z., Tesio L., Rong G.W., Haziot A., et al. Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc Natl Acad Sci USA 90 (1993) 2380-2384
42. Furusako S., Takahashi T., Mori S., Takahashi Y., Tsuda T., Namba M., et al. Protection of mice from LPS-induced shock by CD14 antisense oligonucleotide. Acta Med Okayama 55 (2001) 105-115
43. Strandberg Y., Gray C., Vuocolo T., Donaldson L., Broadway M., and Tellam R. Lipopolysaccharide and lipoteichoic acid induce different innate immune responses in bovine mammary epithelial cells. Cytokine 31 (2005) 72-86
44. Dobrovolskaia M.A., and Vogel S.N. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect 4 (2002) 903-914
45. Wang J.S., Chen Y.W., Chow S.E., Ou H.C., and Sheu W.H. Exercise paradoxically modulates oxidized low density lipoprotein-induced adhesion molecules expression and trans-endothelial migration of monocyte in men. Thromb Haemost 94 (2005) 846-852
46. Navab M., Berliner J.A., Subbanagounder G., Hama S., Lusis A.J., Castellani L.W., et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21 (2001) 481-488
47. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., and Fogelman A.M. Mechanisms of disease: proatherogenic HDL-an evolving field. Nat Clin Pract Endocrinol Metab 2 (2006) 504-511
48. Tardif J.C., Gregoire J., L'Allier P.L., Ibrahim R., Lesperance J., Heinonen T.M., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 (2007) 1675-1682
49. Hubsch A.P., Casas A.T., and Doran J.E. Protective effects of reconstituted high density lipoproteins in rabbit gram negative bacteremia models. J Lab Clin Med 126 (1995) 548-558
50. Nanjee M.N., Crouse J.R., King J.M., Hovorka R., Rees S.E., Carson E.R., et al. Effects of intravenous infusion of lipid-free ApoA-I in humans. Arterioscler Thromb Vasc Biol 16 (1996) 1203-1214
51. Kee P., Rye K.A., Taylor J.L., Barrett P., and Barter P.J. Metabolism of ApoA-I as lipid-free protein or as component of discoidal and spherical reconstituted HDLs: studies in wild-type and hepatic lipase transgenic rabbits. Arterioscler Thromb Vasc Biol 22 (2002) 1912-1917
52. 1 HDL in human plasma. J Lipid Res 49 (2008) 581-587
53. Rye K.A., and Barter P.J. Antiinflammatory actions of HDL: a new insight. Arterioscler Thromb Vasc Biol 28 (2008) 1890-1891